Bellerophon Therapeutics (BLPH) Given Daily Media Impact Score of 0.11

News headlines about Bellerophon Therapeutics (NASDAQ:BLPH) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.8615064197455 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

BLPH has been the topic of a number of recent research reports. Zacks Investment Research raised Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Tuesday, August 29th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Bellerophon Therapeutics in a report on Wednesday, September 6th. Finally, ValuEngine raised Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th.

Bellerophon Therapeutics (BLPH) opened at $2.21 on Tuesday. Bellerophon Therapeutics has a twelve month low of $0.48 and a twelve month high of $2.44.

WARNING: “Bellerophon Therapeutics (BLPH) Given Daily Media Impact Score of 0.11” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply